Comparative Pharmacology
Head-to-head clinical analysis: QUELICIN PRESERVATIVE FREE versus SUCOSTRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUELICIN PRESERVATIVE FREE versus SUCOSTRIN.
QUELICIN PRESERVATIVE FREE vs SUCOSTRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Depolarizing neuromuscular blocker that binds to nicotinic acetylcholine receptors at the motor end-plate, causing initial depolarization followed by sustained membrane depolarization and neuromuscular blockade.
Succinylcholine is a depolarizing neuromuscular blocker that binds to and activates nicotinic acetylcholine receptors at the neuromuscular junction, causing initial muscle fasciculations followed by prolonged depolarization and receptor desensitization, resulting in neuromuscular blockade.
1.0-2.0 mg/kg intravenously; 0.3-1.1 mg/kg intramuscularly. For intravenous administration, typical adult dose is 40-100 mg. Repeat doses of 0.04-0.07 mg/kg as needed for maintenance.
IV: 0.3-1.1 mg/kg initially, then maintenance of 0.04-0.07 mg/kg as needed or continuous infusion of 2.5-4.3 mg/min.
None Documented
None Documented
2 to 4 minutes (pseudocholinesterase-mediated hydrolysis); prolonged in patients with atypical pseudocholinesterase or hepatic impairment.
Terminal elimination half-life is approximately 2-4 minutes for succinylcholine (rapid hydrolysis by plasma pseudocholinesterase). In patients with atypical pseudocholinesterase or deficiency, half-life may be prolonged to 20-60 minutes, leading to prolonged paralysis.
Primarily hydrolyzed by plasma pseudocholinesterase; less than 2% excreted unchanged in urine; minimal biliary/fecal elimination.
Primarily renal excretion of unchanged drug and metabolites (succinylmonocholine); minimal biliary/fecal elimination (<2%). Approximately 10-20% excreted unchanged in urine, with the remainder as succinylmonocholine.
Category C
Category C
Neuromuscular Blocker (Depolarizing)
Neuromuscular Blocker (Depolarizing)